INNOVATIVE EYEWEAR INC (LUCY)
US45791D1090 - Common Stock
We assign a fundamental rating of 4 out of 10 to LUCY. LUCY was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While LUCY has a great health rating, there are worries on its profitability. LUCY is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
LUCY had negative earnings in the past year.
LUCY had a negative operating cash flow in the past year.
LUCY had negative earnings in each of the past 5 years.
In the past 5 years LUCY always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of LUCY (-69.28%) is worse than 74.73% of its industry peers.
Looking at the Return On Equity, with a value of -73.50%, LUCY is doing worse than 60.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.28% | ||
| ROE | -73.5% | ||
| ROIC | N/A |
ROA(3y)-207.79%
ROA(5y)N/A
ROE(3y)-601.34%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LUCY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LUCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LUCY has been reduced compared to 1 year ago.
LUCY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 7.98 indicates that LUCY is not in any danger for bankruptcy at the moment.
LUCY has a better Altman-Z score (7.98) than 86.56% of its industry peers.
There is no outstanding debt for LUCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.98 |
ROIC/WACCN/A
WACC9.2%
2.3 Liquidity
A Current Ratio of 16.83 indicates that LUCY has no problem at all paying its short term obligations.
LUCY's Current ratio of 16.83 is amongst the best of the industry. LUCY outperforms 98.39% of its industry peers.
LUCY has a Quick Ratio of 15.43. This indicates that LUCY is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of LUCY (15.43) is better than 97.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.83 | ||
| Quick Ratio | 15.43 |
3. Growth
3.1 Past
LUCY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -219.76%.
LUCY shows a strong growth in Revenue. In the last year, the Revenue has grown by 159.44%.
LUCY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 167.81% yearly.
EPS 1Y (TTM)-219.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.75%
Revenue 1Y (TTM)159.44%
Revenue growth 3Y167.81%
Revenue growth 5YN/A
Sales Q2Q%14.75%
3.2 Future
The Earnings Per Share is expected to grow by 29.10% on average over the next years. This is a very strong growth
LUCY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 347.21% yearly.
EPS Next Y35%
EPS Next 2Y29.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year171.43%
Revenue Next 2Y347.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LUCY. In the last year negative earnings were reported.
Also next year LUCY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LUCY's earnings are expected to grow with 29.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.1%
EPS Next 3YN/A
5. Dividend
5.1 Amount
LUCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INNOVATIVE EYEWEAR INC
NASDAQ:LUCY (1/3/2025, 8:00:01 PM)
After market: 5.58 +0.04 (+0.72%)5.54
+0.15 (+2.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners1.26%
Inst Owner Change-78.98%
Ins Owners63.7%
Ins Owner Change3.4%
Market Cap13.52M
Analysts82.86
Price Target14.28 (157.76%)
Short Float %3.09%
Short Ratio0.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.38%
Min EPS beat(2)-14.58%
Max EPS beat(2)39.34%
EPS beat(4)2
Avg EPS beat(4)1.3%
Min EPS beat(4)-33.05%
Max EPS beat(4)39.34%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-69.37%
Min Revenue beat(2)-72.37%
Max Revenue beat(2)-66.37%
Revenue beat(4)1
Avg Revenue beat(4)4.21%
Min Revenue beat(4)-72.37%
Max Revenue beat(4)201.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1500%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-51.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.24 | ||
| P/tB | 1.29 | ||
| EV/EBITDA | N/A |
EPS(TTM)-9.66
EYN/A
EPS(NY)-4.08
Fwd EYN/A
FCF(TTM)-2.51
FCFYN/A
OCF(TTM)-2.43
OCFYN/A
SpS0.64
BVpS4.48
TBVpS4.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.28% | ||
| ROE | -73.5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-207.79%
ROA(5y)N/A
ROE(3y)-601.34%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 153.96% | ||
| Cap/Sales | 12.65% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 16.83 | ||
| Quick Ratio | 15.43 | ||
| Altman-Z | 7.98 |
F-Score5
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)742.78%
Cap/Depr(5y)N/A
Cap/Sales(3y)24.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-219.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.75%
EPS Next Y35%
EPS Next 2Y29.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)159.44%
Revenue growth 3Y167.81%
Revenue growth 5YN/A
Sales Q2Q%14.75%
Revenue Next Year171.43%
Revenue Next 2Y347.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-136.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-147.18%
OCF growth 3YN/A
OCF growth 5YN/A